Core Viewpoint - The stock of Lijing Pacific (00575) experienced a significant increase, rising over 12% yesterday and more than 35% today, currently trading at 1.05 HKD with a transaction volume of 648,600 HKD. This surge is attributed to the announcement of its subsidiary, Deep Longevity, expanding into the U.S. market in Q1 of next year, targeting a rapidly growing health market valued at over 6.8 trillion USD [1]. Company Summary - Lijing Pacific's stock price has shown a remarkable increase, with a current rise of 31.25% [1]. - The company’s subsidiary, Deep Longevity, is recognized as a leader in AI-driven aging clocks and longevity science [1]. - The expansion plan into the U.S. market is set to position Deep Longevity within the largest and fastest-growing segment of the health market [1]. Industry Summary - The health market, which Deep Longevity aims to enter, is currently valued at over 6.8 trillion USD, indicating substantial growth potential [1].

Core Viewpoint - The stock price of Lattice Technology Pacific (00575) surged over 12% yesterday and increased by more than 35% today, currently trading at 1.05 HKD with a transaction volume of 648,600 HKD [1] Company Summary - Lattice Technology Pacific announced that its wholly-owned subsidiary, Deep Longevity, a leader in AI-driven aging clocks and longevity science, will initiate an expansion plan into the U.S. market in the first quarter of next year [1] - This expansion will position Deep Longevity in the core of the largest and fastest-growing health market globally, which is currently valued at over 6.8 trillion USD [1]

Core Insights - Deep Longevity, Inc is set to expand into the U.S. market in Q1 2026, targeting the rapidly growing health market valued at over $6.8 trillion [1][2] - The company offers clinically validated aging clocks that provide multi-dimensional biological age assessments, surpassing chronological age [1] - Deep Longevity aims to establish a local sales team in the U.S. to drive partnerships with various health-related entities [2] Group 1 - Deep Longevity's expansion into the U.S. is a significant milestone, with plans to capture a share of the $6.8 trillion health market [1][2] - The aging clocks developed by Deep Longevity include BloodAge, MindAge, BiometricAge, EpigeneticAge, and the upcoming FaceAge, providing personalized insights for consumers and healthcare providers [1][2] - The company has received support from numerous peer-reviewed papers and patents for its technology, which integrates various biological and psychological factors [2][3] Group 2 - The initial sales focus will be on the Southeastern U.S., including states like Alabama, Florida, and Georgia, with plans to build high-impact partnerships [2] - Deep Longevity's technology offers a vertical software as a service (SaaS) solution that provides personalized recommendations to improve health and extend healthy lifespan [3]

Core Insights - Deep Longevity, Inc. is set to expand into the U.S. market in Q1 2026, targeting the rapidly growing health market valued at over $6.8 trillion [1][2] - The company offers clinically validated aging clocks that provide multi-dimensional biological age assessments, surpassing chronological age [1][2] - Deep Longevity aims to establish partnerships with various health-related entities to enhance the distribution of its aging solutions [2] Company Expansion - Deep Longevity is forming a local sales team in the U.S., with the first two sales personnel starting on January 1, 2026 [2] - The initial focus of the sales team will be on the Southeastern U.S. states, including Alabama, Arkansas, Florida, Georgia, Kentucky, Louisiana, Mississippi, North Carolina, South Carolina, Tennessee, Virginia, and West Virginia [2] - The CEO of Deep Longevity emphasized the significance of entering the U.S. market as a milestone for the company [2] Technology and Offerings - The company’s aging clocks integrate various biological markers and psychological factors to provide comprehensive biological aging profiles [2][3] - Deep Longevity's technology is supported by numerous peer-reviewed papers and patents, enhancing its credibility in the market [2] - The company offers vertical software-as-a-service (SaaS) solutions that provide personalized recommendations to improve health and extend healthy lifespan [3]

Core Viewpoint - Deep Longevity, Inc. plans to expand into the U.S. market in Q1 2026, targeting the rapidly growing health market valued at over $6.8 trillion [1][2]. Group 1: Expansion Plans - Deep Longevity will establish a local sales team in the U.S., with the first two sales personnel joining on January 1, 2026 [2]. - The initial focus of the sales team will be on the Southeastern U.S. states, including Alabama, Arkansas, Florida, Georgia, Kentucky, Louisiana, Mississippi, North Carolina, South Carolina, Tennessee, Virginia, and West Virginia [2]. Group 2: Product Offerings - The company offers clinically validated aging clocks, including BloodAge, MindAge, BiometricAge, EpigeneticAge, and the upcoming FaceAge, which provide multi-dimensional biological age assessments beyond chronological age [1][2]. - Deep Longevity's technology is supported by numerous peer-reviewed papers and patents, integrating blood biomarkers, epigenetics, psychology, and biology to deliver comprehensive biological aging profiles [2]. Group 3: Business Model - Deep Longevity provides vertical software-as-a-service (SaaS) solutions that offer personalized recommendations to improve health and extend healthy lifespan [3].

（於開曼群島註冊成立之有限公司） （股份代號：���） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈之內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公佈全部或任何部份內容 而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 Deep Longevity, Inc（本公司之全資附屬公司）連同其附屬公司研發在分子、細 胞、器官及心理層面追蹤人類老化的可解釋之人工智能系統。Deep Longevity的 專利深層老化時鐘為消費者、醫生及企業提供垂直型軟件即服務(SaaS)©解決方 案，提供經證實可改善健康狀況並延長健康壽命的個人化建議。更多資訊請瀏覽 www.deeplongevity.com。 自願性更新營運情況 Deep Longevity於二零二六年第一季度戰略進駐美國市場 本公佈乃勵晶太平洋集團有限公司（「本公司」，連同其附屬公司統稱「本集團」）董事 （「董事」）會（「董事會」）按自願基準而作出，以知會本公司股東及潛在投資者下列 有關其營運的最新情況。 本公司今日宣佈，全球可解釋人工智能驅動老化時鐘與長壽科學的領導者Deep Longevity, Inc及其附屬公司 ...

Group 1 - The company, Zhongji Changshou Science, has signed a memorandum of cooperation with Haoshiduo Biotechnology to collaborate on longevity detection and management services [1] - The partnership aims to provide longevity biological products, medical testing, health consulting services, and management solutions within the health industry [1] - The company operates through its subsidiary, Hongfeng Development, which focuses on longevity science research, medical testing, biological products, and management [1] Group 2 - The board believes that the health and longevity science market has significant potential, as affluent customers are increasingly willing to invest in longevity applications to enhance their overall health and immune systems [2] - The memorandum aligns with the company's strategic development plan in the longevity science sector, which is expected to benefit future business growth [2] - The collaboration is anticipated to enhance the company's positioning in the longevity science diagnostics and medical services field, creating new revenue streams for long-term stable growth [2]